Vedolizumab is approved by the FDA for the treatment of moderate to severe Crohn disease or ulcerative colitis, both forms of inflammatory bowel disease (IBD), who have had an inadequate response or loss of response to immunomodulators, tumor necrosis factor inhibitors, or corticosteroid therapy.
Vedolizumab is approved by the FDA for the treatment of moderate to severe Crohn disease (CD) or ulcerative colitis (UC), both forms of inflammatory bowel disease (IBD), who have had an inadequate response or loss of response to immunomodulators, tumor necrosis factor (TNF) inhibitors, or corticosteroid therapy.
A recent study sought to assess the budgetary impact of including vedolizumab in a health plan formulary as a preferred first-line biologic therapy for the treatment of UC and CD rather than only for patients who have previously failed on anti-TNF therapy.
Researchers developed a budget impact model to examine the incremental impact on a health plan’s budget if vedolizumab were to be included among existing preferred first-line biologic treatments. In an effort to reflect current treatment paradigms, researchers modeled the most current treatment options available in potential health plans, including newly approved therapies and biosimilars. “Incorporating a biosimilar in our budget impact analysis of including vedolizumab as a first-line biologic treatment represents a conservative approach, because the use of any biosimilar may result in lower costs for the payer,” wrote the authors.
In order to account for differences among health pans, the study authors considered 3 hypothetical formulary cases before the introduction of vedolizumab:
In total, researchers found that adding vedolizumab as a first-line treatment in Case 1’s hypothetical formulary demonstrated the most cost-savings, which increased from $1.63 million in the first year of the experiment to $4.68 million in the third year. For Case 2, the total annual cost savings increased from $587,000 in the first year to $1.69 million in the third year; and from $134,000 to $378,000 in Case 3. Additionally, real-world dose escalation patterns contributed to the observed differences in cost savings across the plans. In Case 1, the introduction of vedolizumab as a preferred first-line treatment substantially saves on treatment costs because it reduces the use of adalimumab more in Case 1 than in the other cases.
“The inclusion of vedolizumab on parity with existing preferred first-line biologic treatments is expected to have a substantial cost-savings impact to a health plan,” wrote the authors. “The cost-savings in this study were most pronounced in Case 1, when vedolizumab was introduced as a parity-preferred treatment alongside adalimumab as first-line treatment and alongside infliximab as second-line treatment.”
Reference
Wilson M, Lucas A, Cameron A, Luo M. Budget impact of adding vedolizumab to a health plan formulary as another first-line biologic option for ulcerative colitis and Crohn’s disease. Am Health Drug Benefits. 2018;11(5):253-262. PMCID: PMC6207303.
Review: Product Attributes Relevant to Injection-Site Pain, Adalimumab Treatment
May 4th 2024A review article summarizes the product attributes of reference and biosimilar adalimumab products, such as formulation with or without citrate, delivery volume, and needle gauge, relevant to patients’ experience of injection-site pain.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Eye on Pharma: EU Ustekinumab Approval; New Golimumab Data; Evernorth Adds Humira Biosimilar
April 29th 2024The European Union gained a new ustekinumab biosimilar; Alvotech released positive results from a clinical trial evaluating a golimumab biosimilar and the reference products (Simponi and Simponi Aria), and Evernorth announced that it is set to cover an adalimumab biosimilar at zero cost to patients.
Biosimilars Gastroenterology Roundup for January 2024—Podcast Edition
February 4th 2024On this episode of Not So Different, we reminisce on all the major gastroenterology news from January, which brought several reports quantifying how the gastroenterology biosimilar market is progressing and marked the 1-year anniversary of adalimumab biosimilar competition in the US.
AMCP Posters Tackle Interchangeability and Medicaid, Factors Driving Biosimilar Access
April 24th 2024Two posters from the Academy of Managed Care Pharmacy (AMCP) annual meeting explore how an interchangeable insulin glargine biosimilar plays into Medicaid budgets and the top factors driving access to biosimilars.
Patient Perceptions of Switching From the Reference Adalimumab to Amjevita During Its Initial Launch
April 20th 2024In a survey of patients with autoimmune arthritis who had been switched from reference adalimumab (Humira) to biosimilar adalimumab-atto (Amjevita; Amgen), most reported preferring the biosimilar and had no concerns about switching.